Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;24(4):369-377.
doi: 10.1111/jch.14336. Epub 2022 Jan 4.

Cardiovascular risk assessment tools in Asia

Affiliations

Cardiovascular risk assessment tools in Asia

Yuqing Zhang et al. J Clin Hypertens (Greenwich). 2022 Apr.

Abstract

Cardiovascular disease (CVD) is becoming the most important burden to health care systems in most part of the world, especially in Asia. Aiming at identifying high risk individuals and tailoring preventive treatment, many cardiovascular risk assessment tools have been established and most of them were developed in Western countries. However, these cardiovascular risk assessment tools cannot be used interchangeably without recalibration because of the different risk factor profiles (ie, greater absolute burden of hypertension and lower level of total-cholesterol in Asians and higher prevalence of metabolic disorders in South Asians) and different CVD profiles (higher ratio of stroke/coronary heart disease in Asians) between Western and Asian populations. Original risk models such as Prediction for ASCVD Risk in China (China-PAR) and Japan Arteriosclerosis Longitudinal Study (JALS) score have been developed and well validated for specific countries, while most of countries/regions in Asia are using established models. Due to higher incidence of stroke in Asians, risk factors like hypertension should weigh more in cardiovascular risk assessment comparing with Western populations, but their actual proportions should be based on CVD profiles in specific countries/regions. The authors encourage the development of new cardiovascular risk assessment tools for Asians, if possible. Still, modifying established models with native epidemiological data of risk factor as well as CVD is acceptable in regions where health care resources are insufficient.

Keywords: Asian patients; cardiovascular disease; hypertension-general; risk assessment.

PubMed Disclaimer

Conflict of interest statement

Y Zhang has received research grants from Bayer, Novartis, and Shuanghe; and lecture fees from Bayer, Daiichi Sankyo, Novartis, Pfizer, Sanofi, Servier, and Takeda. J Shin has received honoraria and sponsorship to attend seminars from Daiichi Sankyo, Takeda, Menarini, MSD, Bristol‐Myers Squibb, and Sanofi. K Kario received research grant from A &D Co.; Omron Healthcare Co.; Roche Diagnostics KK; MSD KK; Astellas Pharma Inc; Otsuka Holdings Co.; Otsuka Pharmaceutical Co.; Sanofi KK; Shionogi & Co.; Sanwa Kagaku Kenkyusho Co.; Daiichi SankyoCo.; Sumitomo Dainippon Pharma Co.; Takeda Pharmaceutical Co.; Mitsubishi Tanabe Pharma Co.; Teijin Pharma; Boehringer Ingelheim Japan Inc; Pfizer Japan Inc; and Fukuda Denshi Co. S Siddique has received honoraria from Bayer, GlaxoSmithKline, Pfizer, ICI, and Servier; and travel, accommodation, and conference registration support from Atco Pharmaceutical, Highnoon Laboratories, Horizon Pharma, ICI, and Pfizer. Y‐C Chia has received honoraria and sponsorship to attend conferences and CME seminars from Abbott, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Novartis, Orient Europharma, Pfizer, and Sanofi; and a research grant from Pfizer. C‐H Chen has received honoraria as a member of a speaker's bureau for Pfizer. J Sison has received honoraria from Pfizer, AstraZeneca, Boehringer Ingelheim, and Novartis. GP Sogunuru has received a research grant related to hypertension monitoring and treatment from Pfizer. JC Tay has received advisory board and consultant honoraria from Pfizer. JG Wang has received research grants from Bayer, Pfizer, and Phillips; and lecture and consulting fees from Bayer, Daiichi‐Sankyo, Merck Sharp & Dohme, Pfizer, Sanofi, and Servier. All other authors report no potential conflicts of interest in relation to this article.

References

    1. Ohira T, Iso H. Cardiovascular disease epidemiology in Asia: an overview. Circ J. 2013;77(7):1646‐1652. - PubMed
    1. Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population‐based studies from 90 countries. Circulation. 2016;134(6):441‐450. - PMC - PubMed
    1. Peters SAE, Wang X, Lam T‐H, et al. Clustering of risk factors and the risk of incident cardiovascular disease in Asian and Caucasian populations: results from the Asia Pacific Cohort Studies Collaboration. BMJ Open. 2018;8(3):e019335. - PMC - PubMed
    1. D'agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743‐753. - PubMed
    1. Conroy R. Estimation of ten‐year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987‐1003. - PubMed

Publication types